Business Blockbuster - Helpng business to be more visible on Google

Business Daily Media


.

Immuno Cure BioTech acquires Shanghai Teresa Healthcare

Integrating Electroporation Technology & DNA Vaccine Platforms

HONG KONG SAR - Media OutReach - 20 September 2022 - Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, announced today the acquisition of 92.6% of Shanghai Teresa Healthcare, the pioneer of electroporation technology and device in China.

The transaction will be settled in cash and shares. Teresa's shareholders will swap for about 1.5% equity in Immuno Cure while the inventor of Teresa's EP technology, Professor XU Yuhong (徐宇虹), maintains her 7.4% direct equity in Teresa.

Teresa EP device delivers brief electrical pulses to promote efficient penetration of DNA vaccine through cell membrane for the enhancement of gene expression and ultimate immune responses. It is the only such device approved by National Medical Products Administration for the administration of DNA vaccine in China. Such EP technology has been an integral part of Immuno Cure's DNA vaccine delivery strategy from research to clinical stage.

Founded in 2004, Shanghai Teresa is an innovative medical device group focusing in electro immunotherapies and rehabilitation therapies. In 2005, Teresa's electroporation technology was developed to enhance the delivery of DNA medicine, based on the intellectual property generated by Shanghai Jiao Tong University under the National 863 Project. Such EP technology has been proven safe and efficacious after deployment of over 10,000 times in collaboration with more than thirty hospitals for the administration of DNA medicine in numerous human trial subjects.

Immuno Cure has two PD-1-Enhanced DNA vaccines currently in phase 1 clinical trial for prevention of COVID-19 and therapeutic cure of HIV/AIDS.

Dr JIN Xia, CEO of Immuno Cure said, "Immuno Cure has partnered with Teresa over the years in developing customised EP delivery strategy for our PD-1-Enhanced DNA vaccines, which has brought about encouraging results in clinical setting recently. I am pleased with this convergence with Teresa, which will no doubt bring our teams even closer together. Teresa will continue to operate independently while leveraging on Immuno Cure's R&D platform for the development of their next generation non-invasive EP technology for intradermal delivery strategy. Immuno Cure is committed to support the continual growth and success of Teresa."

Ms. CHEN Liye, CEO of Teresa said, "Founded on our long term collaboration, Teresa is excited to become a member of Immuno Cure Group. This move will not only provide us with a much closer R&D relationship, which is essential for our technology advancement but also offer us the financial capability to meet future needs. Teresa treasures our collaborations with other players in the field and look forward to continuing our collaborations with new and sustainable EP technology."

Professor CHEN Zhiwei, Director of AIDS Institute at the University of Hong Kong and the Principal Scientific Advisor of Immuno Cure said, "Our research and development work at the AIDS Institute and Immuno Cure has benefitted from Teresa's EP technology and their diligent collaborative effort over the past 12 years. I am pleased to see their relationship developing into an even closer tie. Look forward to the development of the next generation of EP technology for further optimisation of delivery strategy and patient experience."

Dr Percy CHENG, Chairman of Immuno Cure concludes, "This transaction offers Immuno Cure the opportunity to secure Teresa's EP technology for support of not only R&D but also the clinical administration of our PD-1-Enhanced DNA vaccines. We are pleased with Professor XU's decision to remain as our co-investor in Teresa and are optimistic in the future of EP technology in our DNA vaccine development."Hashtag: #ImmunoCureBiotech

The issuer is solely responsible for the content of this announcement.

Immuno Cure BioTech

Immuno Cure BioTech is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of vaccines and immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-Enhanced DNA vaccine and Anti-Δ42PD1 Blocking Antibody technology platforms.

To learn more about Immuno Cure BioTech, please visit

Shanghai Teresa Healthcare

Founded in 2004, Shanghai Teresa is an innovative medical device group based in Shanghai Zhangjiang Hi-Tech Park, focusing in electro immunotherapies and rehabilitation therapies.

To learn more about Shanghai Teresa Healthcare, please visit




News from Asia

Allianz: Reported AI losses understate the true risk and are only the tip of the iceberg

Allianz Commercial analysis highlights emerging and interconnected risks and claims scenarios related to global AI adoption in businesses.

APEC Gathering Fulfills Shenzhen Vendor’s 25-Year Global Friendship Wish

SHENZHEN, CHINA — Media OutReach Newswire – 19 November 2026 – Amid the ongoing 33rd APEC Economic Leaders' Meeting hosted in Shenzhen, a heartwarming story of cross-border friendship has emerged ...

Viet Nam Takes Global Lead in New Climate-Smart Agrifood Partnership Launched at COP31

ANTALYA, TURKEY– Media OutReach Newswire – 19 November 2026 – Viet Nam has taken a significant step in advancing its role in international climate and food systems diplomacy with the launch of a n...

SACOFA Fortifies Connectivity Partnership to Advance Kenyalang Smart City, witnessed by The Premier of Sarawak

SARAWAK, MALAYSIA – Media OutReach Newswire – 19 November 2026 – SACOFA Sdn Bhd (SACOFA) is strengthening its role as the primary backhaul connectivity and telecommunications infrastructure partne...

Dual Engines Driving the Green Transition! WGO Hosts the "Sustainable Finance Award" and "Sustainable Enterprise Award" to Honour Cross-Sector Pioneers

HONG KONG SAR – Media OutReach Newswire – 19 November 2026 – The World Green Organisation (WGO) proudly hosted the presentation ceremony for the "Sustainable Finance Award" and the "Sustainable En...

From the South China Sea to the Aegean: Nansha Seeks Closer Cooperation with Greece in Coastal Sports and Tourism

GUANGZHOU, CHINA – Media OutReach Newswire – 19 November 2026 – During the China-Greece Sports and Cultural Exchange Week held in Athens on November 3, a delegation from Nansha District, Guangzhou...

Yicura BioMed Holds Pre-Launch Preparation Meeting and IDMC Kick-off Meeting for ICVAX-201 Clinical Project

ICVAX® Phase II Clinical Study Enters Key Preparation StageBEIJING, CHINA – Media OutReach Newswire – 19 November 2026 – Yicura BioMed held the Pre-launch Preparation Meeting and the Independent D...

Advanced Robotics Conference 2026: FEV highlights pathways to industrial deployment of Physical AI

AACHEN, GERMANY – Newsaktuell – 19 November 2026 – The Advanced Robotics Conference (ARC) 2026 will bring together leading representatives from international technology companies, star...

LANDMARK’s ‘Destination CENTRAL’ Opens an Inspiring New Chapter for the Festive Season in Hong Kong

Heightening the Global Momentum of Louis Vuitton’s Monumental Façade and Welcoming the Arrival of “Christmas at The Gloucester Hotel”HONG KONG SAR – Media OutReach Newswire – 19 November 2026 –Thi...

AXS and PayerMax Advance Omnichannel Payment Acceptance for Merchants

SINGAPORE – Media OutReach Newswire – 19 November 2026 – AXS Pte Ltd (AXS), a leading bill management and payment acceptance solutions provider, and PayerMax, a global payment solutions provider, ...

New Research Highlights What Australian Retailers Need to Deliver

New research among Australian SHEIN customers reveals how price comparisons, product quality and customer reviews are shaping purcha...

Why the secrecy around car insurance?

Every year, millions of Australians receive their car insurance renewal and promise themselves they’ll look at it properly later. Then life gets in ...

Australian workers spend almost an hour a day administering email

Research finds email filing, searching and rework consuming an estimated 58 minutes a day and potentially exposing organisations to millionsAustralian...

Customer Service Is Becoming Part of the Small Business Sales and Marketing Engine

For Customer Service Week, 5-9 October, Thryv is urging small businesses to look beyond generating  enquiries and examine what happens after a custome...

Gift Cards as the gateway to agentic payments

Prepaid and stored value gives consumers the trust and control to try AI shopping agents By Blackhawk Network VP Head of ANZ Kieran Nolan For deca...

Why Data Accumulation Without Governance Undermines Sustainability Goals

In July 2026, Group 2 entities, the second cohort of Australian businesses, began their first reporting period under the mandatory climate disclosur...